These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10426668)

  • 1. A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma.
    Berg WJ; McCaffrey J; Schwartz LH; Mariani T; Mazumdar M; Motzer RJ
    Invest New Drugs; 1998-1999; 16(4):337-40. PubMed ID: 10426668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.
    Berg WJ; Schwartz L; Yu R; Mazumdar M; Motzer RJ
    Invest New Drugs; 2001; 19(4):317-20. PubMed ID: 11561691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma.
    Kuebler JP; King GW; Triozzi P; Moore T; Kraut EH
    Invest New Drugs; 2001; 19(4):327-8. PubMed ID: 11561693
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma.
    Berg WJ; Schwartz LH; Amsterdam A; Mazumdar M; Vlamis V; Law TM; Nanus DM; Motzer RJ
    Invest New Drugs; 1997; 15(4):353-5. PubMed ID: 9547678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
    Zalupski MM; Philip PA; LoRusso P; Shields AF
    Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
    Zalupski MM; Shields AF; Philip PA; Kraut M; LoRusso P; Heilbrun LK; Vaitkevicius V
    Invest New Drugs; 1998; 16(1):93-6. PubMed ID: 9740550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
    Vuky J; McCaffrey J; Ginsberg M; Mariani T; Bajorin DF; Bosl GJ; Motzer RJ
    Invest New Drugs; 2000 Aug; 18(3):265-7. PubMed ID: 10958596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Lucci JA; Hurteau JA
    Invest New Drugs; 2001; 19(1):77-80. PubMed ID: 11291835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.
    Vuky J; Yu R; Schwartz L; Motzer RJ
    Invest New Drugs; 2002 Aug; 20(3):327-30. PubMed ID: 12201495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
    Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Morgan MA; Carlson J;
    Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study.
    Bastasch M; Panella TJ; Kretzschmer SL; Graham D; Mayo M; Williamson S
    Invest New Drugs; 2002 Aug; 20(3):339-42. PubMed ID: 12201497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Icasiano E; Higgins G; Herr H; Bajorin DF
    Invest New Drugs; 2000 Aug; 18(3):247-51. PubMed ID: 10958593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
    Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
    Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.
    Ramaswamy B; Mrozek E; Kuebler JP; Bekaii-Saab T; Kraut EH
    Invest New Drugs; 2011 Apr; 29(2):347-51. PubMed ID: 19844661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.
    Allen A; Wolf M; Crawford ED; Davis MP; Natale RB; Barnett ML
    Invest New Drugs; 1992 Jul; 10(2):129-32. PubMed ID: 1500267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.
    Ronnen EA; Kondagunta GV; Ishill N; Sweeney SM; Deluca JK; Schwartz L; Bacik J; Motzer RJ
    Invest New Drugs; 2006 Nov; 24(6):543-6. PubMed ID: 16832603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
    Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
    Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.